A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination

Drijkoningen, 2014, Pneumococcal infection in adults: burden of disease, Clin Microbiol Infect, 20, 45, 10.1111/1469-0691.12461 Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, AGEDD Adult Pneumococcal Burden Study Team, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratalà J, Chang FY, Charles PG, Diaz AA, Domínguez J, Ehara N, Endeman H, Falcó V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Mareković I, Masiá M, Matta MA, Miró Ò, Murdoch DR, Nuermberger E, Paolini R, Perelló R, Snijders D, Plečko V, Sordé R, Strålin K, van der Eerden MM, Vila-Corcoles, Watt JP. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013;8:e60273. https://dx.doi.org/10.1371/journal.pone.0060273. 2012, Pneumococcal vaccines WHO position paper--2012, Wkly Epidemiol Rec, 87, 129 GBD 2016. Lower respiratory infections collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis 2018;18(11):1191–1210. https://dx.doi.org/10.1016/S1473-3099(18)30310-4. Jain, 2015, Community-acquired pneumonia requiring hospitalization among U.S. adults, N Engl J Med, 373, 415, 10.1056/NEJMoa1500245 2012, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 61, 816 GBD 2015. LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis 2017;17(11):1133–1161. https://dx.doi.org/10.1016/S1473-3099(17)30396-1. Geno, 2015, Pneumococcal capsules and their types: past, present, and future, Clin Microbiol Rev, 28, 871, 10.1128/CMR.00024-15 Pilishvili, 2015, Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines, Vaccine, 33, D60, 10.1016/j.vaccine.2015.05.102 Jackson, 2013, Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older, Vaccine, 31, 3594, 10.1016/j.vaccine.2013.04.084 Frenck, 2016, Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older, Vaccine, 34, 3454, 10.1016/j.vaccine.2016.04.093 Bonten, 2015, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med, 372, 1114, 10.1056/NEJMoa1408544 McLaughlin, 2018, Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design, Clin Infect Dis, 67, 1498 Centers for Disease Control and Prevention., 1984, Recommendations of the Immunization Practices Advisory Committee (ACIP) update: pneumococcal polysaccharide vaccine usage – United States, MMWR Recomm Rep, 33, 273 Tomczyk, 2014, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 63, 822 Matanock, 2019, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep, 68, 1069, 10.15585/mmwr.mm6846a5 Gierke R. Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among adults, United States, Centers for Disease Control and Prevention, https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/24-25/02-Pneumococcal-Gierke.pdf; 2021 [accessed April 14, 2021]. Moore, 2015, Impact of 13-valent pneumococcal conjugate vaccine used in children on invasive pneumococcal disease in children and adults in the United States: analysis of multisite, population-based surveillance, Lancet Infect Dis, 15, 301, 10.1016/S1473-3099(14)71081-3 Cohen, 2017, Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries, Expert Rev Vaccines, 16, 625, 10.1080/14760584.2017.1320221 World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper - February 2019, https://apps.who.int/iris/bitstream/handle/10665/310968/WER9408.pdf?ua=1; 2019 [accessed September 23, 2020]. Pilishvili T, Gierke R, Farley M, Schaffner W, Thomas A, Reingold A, et al. Epidemiology of invasive pneumococcal disease (IPD) following 18 years of pneumococcal conjugate vaccine (PCV) use in the United States. In: IDWeek; 2020 October 21; Virtual. Hausdorff, 2016, Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement, Hum Vaccin Immunother, 12, 358, 10.1080/21645515.2015.1118593 Isturiz, 2019, Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia, Vaccine, 37, 3352, 10.1016/j.vaccine.2019.04.087 van der Linden, 2015, Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany, PLoS One, 10, e0131494, 10.1371/journal.pone.0131494 Pfizer Inc. U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older, https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent; 2021 [accessed June 14, 2021]. Balsells, 2017, Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis, PLoS ONE, 12, e0177113, 10.1371/journal.pone.0177113 Cohen, 2016, The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014, Hum Vaccin Immunother, 12, 277, 10.1080/21645515.2015.1116654 Cohen, 2020, Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation, Clin Infect Dis, 72, 10.1093/cid/ciaa917 Cui, 2017, Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world, Hum Vaccin Immunother, 13, 1229, 10.1080/21645515.2016.1277300 Lepoutre, 2008, Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006, Euro Surveill, 13, 18962, 10.2807/ese.13.35.18962-en Metcalf, 2016, Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA, Clin Microbiol Infect, 22, 60.e9, 10.1016/j.cmi.2015.08.027 Moore, 2015, Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance, Lancet Infect Dis, 15, 301, 10.1016/S1473-3099(14)71081-3 Tomczyk, 2016, Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine, Clin Infect Dis, 62, 1119, 10.1093/cid/ciw067 van der Linden, 2019, Limited indirect effects of an infant pneumococcal vaccination program in an aging population, PLoS One, 14, e0220453, 10.1371/journal.pone.0220453 Wantuch, 2019, Invasive pneumococcal disease in relation to vaccine type serotypes, Hum Vaccin Immunother, 15, 874, 10.1080/21645515.2018.1564444 Yahiaoui, 2018, Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries, BMC Infect Dis, 18, 440, 10.1186/s12879-018-3341-0 Zintgraff, 2020, Distribution of PCV13 and PPSV23 Streptococcus pneumoniae serotypes in Argentinean adults with invasive disease, 2013–2017, Rev Argent Microbiol, 52, 189 Kalina, 2020, Qualification and clinical validation of an immunodiagnostic assay for detecting 11 additional S. pneumoniae serotype-specific polysaccharides in human urine, Clin Infect Dis, 71, e430 Pneumovax® 23 (pneumococcal vaccine polyvalent). Full Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, 2015. Perdrizet J, Chilson E, Wasserman M, Farkouh RA, Sato R. Current and future pneumococcal conjugate vaccine serotype-specific burden in the United States adult population. in: International Symposium on Pneumococci and Pneumococcal Diseases-12; 2020 June 21-25; Toronto, Canada. de Miguel, 2020, Nationwide trends of invasive pneumococcal disease in Spain (2009–2019) in children and adults during the pneumococcal conjugate vaccine era, Clin Infect Dis Castiglia, 2014, Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe, Adv Ther, 31, 1011, 10.1007/s12325-014-0157-1 Williams, 2016, Surveillance of vaccination coverage among adult populations - United States, 2014, MMWR Surveill Summ, 65, 1, 10.15585/mmwr.ss6501a1 McLaughlin, 2019, Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States, Hum Vaccin Immunother, 15, 841, 10.1080/21645515.2018.1564434 Clutterbuck, 2012, Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells, J Infect Dis, 205, 1408, 10.1093/infdis/jis212 Greenberg, 2014, Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age, Vaccine, 32, 2364, 10.1016/j.vaccine.2014.02.002 Jackson, 2013, Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine, Vaccine, 31, 3585, 10.1016/j.vaccine.2013.05.010 Schmoele-Thoma, 2019, Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults, Hum Vaccin Immunother, 15, 575, 10.1080/21645515.2018.1538618 Glesby, 2015, Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine, J Infect Dis, 212, 18, 10.1093/infdis/jiu631 van Deursen, 2017, Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), Clin Infect Dis, 65, 787, 10.1093/cid/cix419